Literature DB >> 25446567

Mechanisms of Nattokinase in protection of cerebral ischemia.

Hongrui Ji1, Liang Yu2, Keyu Liu3, Zhigang Yu2, Qian Zhang2, Fengjuan Zou2, Bo Liu2.   

Abstract

In vivo, the level of cyclic Adenosine Monophosphate (cAMP) and the pathway of the Janus Kinase1/Signal Transducers and Activators of Transcription1 (JAK1/STAT1) were studied. In vitro, the Ca(2+) mobilization in human platelet stimulated by thrombin was observed. In addition, vasomotion of vascular smooth muscle was measured by adding KCl or norepinephrine(NE) under the Ca(2+) contained bath solutions. The effect induced by NE in the presence of N-nitro-L-arginine methyl ester (L-NAME) or indometacin (Indo) was also detected. At last, the levels of tissue plasminogen activator (t-PA) and Plasminogen activator inhibitor-1 (PAI-1) in cultured supernatans in Human umbilical vein endothelial cells (Huvecs) were measured by means of ELISA kit. Results showed that Nattokinase (NK) significantly increased the cAMP level, activated the signal passage of JAK1/STAT1 in injured part and inhibited remarkably the rise of platelet intracellular Ca(2+) ([Ca(2+)]i) in human platelet. Furthermore, NK relaxed rat thoracic aortic artery in the dose-dependent manner and in the endothelium dependent manner and its effect could be attenuated by L-NAME. Also, the secretion of t-PA and PAI-1 were reduced stimulated by Adr on Huvecs. These data indicated that the neuroprotective effect of NK was associated with its antiplatelet activity by elevating cAMP level and attenuating the calcium release from calcium stores; with its anti-apoptotic effect through the activation of JAK1/STAT1 pathway; with its relaxing vascular smooth muscle by promoting synthesis and release of NO, reducing ROC calcium ion influx and with its protection on endothelial cells through increasing fibrinolytic activity and facilitating spontaneous thrombolysis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cyclic adenosine monophosphate; Human umbilical vein endothelial cells; Janus kinase1/signal transducers and activators of transcription1; Nattokinase; Plasminogen activator inhibitor-1; Tissue plasminogen activator

Mesh:

Substances:

Year:  2014        PMID: 25446567     DOI: 10.1016/j.ejphar.2014.10.024

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Recent Advances in Nattokinase-Enriched Fermented Soybean Foods: A Review.

Authors:  Danfeng Li; Lizhen Hou; Miao Hu; Yaxin Gao; Zhiliang Tian; Bei Fan; Shuying Li; Fengzhong Wang
Journal:  Foods       Date:  2022-06-24

2.  Nattokinase Attenuates Retinal Neovascularization Via Modulation of Nrf2/HO-1 and Glial Activation.

Authors:  Zijing Huang; Tsz Kin Ng; Weiqi Chen; Xiaowei Sun; Dingguo Huang; Dezhi Zheng; Jingsheng Yi; Yanxuan Xu; Xi Zhuang; Shaolang Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-05-03       Impact factor: 4.799

3.  A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.

Authors:  Yuko Kurosawa; Shinsuke Nirengi; Toshiyuki Homma; Kazuki Esaki; Mitsuhiro Ohta; Joseph F Clark; Takafumi Hamaoka
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

4.  Nattospes as Effective and Safe Functional Supplements in Management of Stroke.

Authors:  Phuong T Pham; Bo Han; Ba X Hoang
Journal:  J Med Food       Date:  2020-01-14       Impact factor: 2.786

5.  Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.

Authors:  Giuseppe Gallelli; Giulio Di Mizio; Caterina Palleria; Antonio Siniscalchi; Paolo Rubino; Lucia Muraca; Erika Cione; Monica Salerno; Giovambattista De Sarro; Luca Gallelli
Journal:  Nutrients       Date:  2021-06-13       Impact factor: 5.717

Review 6.  Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases.

Authors:  Hongjie Chen; Eileen M McGowan; Nina Ren; Sara Lal; Najah Nassif; Fatima Shad-Kaneez; Xianqin Qu; Yiguang Lin
Journal:  Biomark Insights       Date:  2018-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.